The Regulatory Landscape Is More Complex Than “Approved vs. Banned”
Most discussions of peptide legality reduce to a simple binary: FDA approved (legal) vs. not approved (illegal/grey). The reality is considerably more nuanced. There are at least five distinct legal categories for peptides in the United States, and which category applies to a given compound significantly changes what’s permissible.
This guide is intended to be a clear, factual reference — not legal advice. Regulatory status changes. Verify current status with a healthcare attorney or your state pharmacy board if specific decisions depend on it.
The Five Categories
Category 1: FDA-Approved Drugs
These peptides have completed the full NDA (New Drug Application) or BLA (Biologics License Application) pathway. They are approved for specific indications and manufactured under Good Manufacturing Practice (GMP) by the approved manufacturer.
Examples: Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro/Zepbound), Teriparatide (Forteo), PT-141 (Vyleesi), Ziconotide (Prialt), Octreotide (Sandostatin), Leuprolide (Lupron)
Legal status: Fully legal. Can be prescribed, dispensed, and used per labeling (and off-label by physician decision).
Category 2: Off-Label Use of FDA-Approved Drugs
Physicians may legally prescribe any FDA-approved drug for any indication they believe is clinically appropriate — this is called off-label prescribing. Off-label prescribing accounts for approximately 20% of all prescriptions in the US.
Examples: Sermorelin (approved for pediatric GH deficiency; prescribed off-label for adult hormone optimization), Oxytocin (approved for labor induction; used off-label for social anxiety, HSDD), Thymosin Alpha-1 (Zadaxin, approved in 35+ countries but not FDA-approved; used as a research compound in the US).
Legal status: Off-label prescribing is legal. The drug itself must still be manufactured by an FDA-approved source (or compounded under appropriate rules).
Category 3: Compounded Medications Under 503A
Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. Under 503A:
- A licensed pharmacist or physician can compound a drug for an identified individual patient
- The compound must be based on a valid prescription
- Bulk drug substances used must be FDA-approved, or on the FDA’s 503A Bulks List
- Compounds may not be “essentially a copy” of a commercially available drug
This is where most peptide prescribing has historically occurred. Sermorelin, oxytocin, PT-141 (in alternate formulations), and historically BPC-157, TB-500, CJC-1295, and ipamorelin were available from 503A compounding pharmacies.
Key 2024 Development: After declaring the GLP-1 shortage resolved, the FDA began enforcement action against compounding pharmacies producing semaglutide and tirzepatide, as compounding a copy of an available drug is prohibited.
Category 4: Bulk Drug Substances — Category 2 Prohibited List
The FDA maintains a list of bulk drug substances that cannot be used in 503A compounding. This list has expanded significantly in recent years and now includes many popular research peptides:
Substances on the 503A prohibited/Category 2 list (as of 2025):
- BPC-157
- TB-500 (Thymosin Beta-4)
- Epitalon
- GHK-Cu (for injection)
- Selank (injection)
- Semax (injection)
- AOD-9604
- Humanin
- MOTS-c
- IGF-1 LR3
Legal consequence: US compounding pharmacies cannot prepare these for human use. They are not “banned substances” — they remain legal to possess as research chemicals — but the compounded pharmacy pathway is closed.
Category 5: Research Chemicals (“Not for Human Use”)
Many peptides are sold legally as “research chemicals” by companies that explicitly label them “not for human use.” This is a legal grey zone:
- Manufacturing: No GMP requirements; quality varies enormously
- Sale: Legal if not marketed for human use
- Purchase: Legal for adults in most US states
- Administration: Legal in most jurisdictions, but no medical oversight or liability structure
The risk: “Research grade” peptides may contain impurities, incorrect concentrations, or bacterial endotoxins that would be caught by pharmacy QC. Without mandatory testing, you are relying entirely on supplier integrity.
The 2024-2025 Compounding Enforcement Wave
Several developments significantly changed the compounding landscape:
GLP-1 Shortage Resolution (2024): When FDA declared the semaglutide shortage resolved, compounded semaglutide became impermissible. Pharmacies were given wind-down periods. Tirzepatide compounding similarly came under pressure. This affected hundreds of thousands of patients who had been receiving compounded versions at lower cost.
Peptide Category 2 Additions: The FDA formally added multiple research peptides to the prohibited compounding list following review. This closed the previously grey pathway for compounds like BPC-157 and TB-500.
503B Outsourcing Facilities: Some substances prohibited under 503A may still be available under 503B (outsourcing facility) rules for clinical settings. This is a different regulatory pathway with stricter GMP requirements.
Practical Implications by Compound
| Compound | FDA Approval | 503A Status | Available How |
|---|---|---|---|
| Semaglutide | ✅ Approved | ❌ Shortage resolved | Brand only (Wegovy/Ozempic) |
| Tirzepatide | ✅ Approved | ❌ Shortage ended | Brand only (Mounjaro/Zepbound) |
| Sermorelin | ❌ Withdrawn | ✅ Permitted | 503A pharmacy (Rx required) |
| PT-141 | ✅ Approved | ✅ Alternate forms | Brand or 503A |
| BPC-157 | ❌ None | ❌ Prohibited | Research chemical only |
| TB-500 | ❌ None | ❌ Prohibited | Research chemical only |
| CJC-1295 | ❌ None | ⚠️ Uncertain | Verify with pharmacy |
| Ipamorelin | ❌ None | ⚠️ Uncertain | Verify with pharmacy |
| GHK-Cu (topical) | ❌ None | ✅ Topical OK | Compounded topical |
| Epitalon | ❌ None | ❌ Prohibited | Research chemical only |
| Thymosin Alpha-1 | ❌ (US) | ⚠️ Verify | Variable |
This table reflects known status as of 2025. Verify current status before making decisions.
WADA Prohibited List (For Athletes)
Separate from FDA regulations, the World Anti-Doping Agency (WADA) maintains its own prohibited substance list relevant to athletes in sanctioned competition:
WADA-Prohibited Peptides (S2 — Peptide Hormones, Growth Factors):
- All GH secretagogues (CJC-1295, Ipamorelin, GHRP-2, GHRP-6, MK-677, Sermorelin)
- IGF-1 and analogs
- TB-500 (Thymosin Beta-4)
- Erythropoietin (EPO)
- Mecasermin
Important: WADA prohibition applies regardless of FDA approval status. Athletes should assume any GH-axis or tissue repair peptide is prohibited unless confirmed otherwise with their sport’s governing body.
How Regulation Will Likely Evolve
Several trends are worth watching:
-
Continued 503A restriction expansion: The FDA’s bulk drug substance review process continues. More compounds are likely to be added to the prohibited list.
-
More approved GLP-1 options: Multiple next-generation GLP-1/GIP/glucagon agonists (retatrutide, etc.) are in Phase III, with approvals expected 2025–2027.
-
First BPC-157 or similar IND: If a biotech company files an IND (Investigational New Drug Application) for BPC-157 or TB-500, it would begin a formal approval process that could eventually legitimize these compounds — but likely take a decade.
-
State-Level Variation: Some states have more permissive pharmacy rules than others; this creates variation in what’s practically available via prescription.
What This Means for Patients
If you’re using FDA-approved peptides: You’re in the most protected position — pharmaceutical-grade manufacturing, physician oversight, and a pharmacovigilance system.
If you’re using off-label compounded peptides: Verify with your pharmacy that the compound is legally permissible under current 503A rules. The landscape changed significantly in 2023–2024.
If you’re using research chemicals: Understand that you are entirely outside the regulatory protection system. Quality, purity, and accurate dosing are your personal responsibility. At minimum: COA from an independent third-party testing laboratory is non-negotiable.